Real-world treatment patterns, adverse events (AEs) and outcomes associated with Bacillus Calmette-Guerin (BCG) use for non-muscle invasive bladder cancer (NMIBC) in the United States. (February 2017) - Malangone-Monaco, E.; Wilson, K.; Satram-Hoang, S.; Diakun, D.; Lin, S.W.; Tayama, D.; Ogale, S.